Alpha Cognition Inc (ACOG)

Alpha Cognition Inc. (NASDAQ:ACOG) Receives Average Recommendation of “Buy” from Brokerages

Alpha Cognition to Present New ZUNVEYL® (Benzgalantamine) Clinical and Real-World Data at ASCP Annual Meeting and NEI Fall Congress

Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Alpha Cognition Announces CONVERGE Real-World Evidence on ZUNVEYL®(Benzgalantamine) Use in Long-Term Care

Reviewing Alpha Cognition (NASDAQ:ACOG) & Karyopharm Therapeutics (NASDAQ:KPTI)

Analysts Set Alpha Cognition Inc. (NASDAQ:ACOG) Target Price at $18.00

Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) 2Q26

Alpha Cognition Inc. (ACOG) Q2 2026 Earnings Call Transcript

Alpha Cognition Inc. (ACOG) Reports Q2 Loss, Tops Revenue Estimates

Alpha Cognition Q2 Earnings Call Highlights

Alpha Cognition Inc. Reports Second Quarter 2026 Financial Results and Provides Operational Update

Alpha Cognition Inc. (ACOG) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Alpha Cognition to Report Second Quarter 2026 Financial Results and Provide Business Update

Alpha Cognition Receives European Patent Covering ZUNVEYL® for the Treatment of Mild-to-Moderate Alzheimer's Disease

Alpha Cognition Inc. (ACOG) Surges 8.6%: Is This an Indication of Further Gains?

Playing The Biotech Breakout With Insiders

Alpha Cognition to Participate in Panel Discussion at the B. Riley Securities Mind, Muscle & Vision Summit